Edwards Lifesciences raises its 2026 outlook after first quarter revenue grew 16.7% driven by strong TAVR performance.

Edwards Lifesciences reported first quarter 2026 revenue of $1.65 billion and adjusted EPS of $0.78, beating analyst estimates. Following the strong results, the company raised its full-year 2026 guidance for both sales and adjusted EPS.

Key Highlights

• Transcatheter Aortic Valve Replacement (TAVR) sales grew 14.4% year-over-year to $1.20 billion, representing 11.0% growth on a constant currency basis.
• The company raised its full-year 2026 constant currency sales growth guidance to a range of 9% to 11% and its adjusted EPS outlook to a new range of $2.95 to $3.05.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales increased 51.9% from the prior year to $175.1 million, driven by its portfolio of repair and replacement therapies.